Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: F. Hoffmann-La Roche Ltd
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
An open-label, non-controlled study of bevacizumab in combination with cisplatin-gembitabine or carboplatin-paclitaxel, as first line treatment for patients with advanced or recurrent squamous non-small cell lung cancer (NSCLC)
To assess the feasibility of using bevacizumab plus cisplatingemcitabine or carboplatin-paclitaxel in patients with squamous NSCLC considered to be at major risk for pulmonary haemorrhage*, when using...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients who are Chemotherapy-Naive and have Stage IV Non-Squamous Non-Small Cell Lung Cancer
•To evaluate the efficacy of atezolizumab (atezo) as measured by investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1....
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multiple doses in patients with Type 2 diabetes
To evaluate the effect of taspoglutide on gastric emptying (as assessed by the pharmacokinetics of paracetamol) after first and multiple dose of taspoglutide.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A study of the safety, efficacy, and tolerability of combination treatment of setrobuvir, danoprevir, ritonavir, and Copegus® with or without mericitabine in patients infected with the Hepatitis C virus who never received treatment before
• To evaluate the safety, tolerability and efficacy (SVR-12) of 12 or 24 weeks of treatment with an IFN-free regimen of STV, DNV/r, and RBV, with or without MCB, in treatment-naïve CHC genotype 1 pati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients < 4 months of age
Definir la farmacocinética de ganciclovir tras la administración de valganciclovir polvo para solución oral en pacientes pediátricos <4 meses de edad receptores de trasplante cardíaco.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors
P Ib: • To characterize the safety and tolerability of R1507 administered every 3 weeks in combination with daily RAD001 and to determine the maximum-tolerated dose (MTD) of RAD001 administered orally...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A clinical study conducted at many clinical sites. In this study patients will be randomly assigned to one of two treatments. Neither staff at the site nor the patient nor the sponsor’s team will know if the patient received drug with an active ingredient or drug without an active ingredient. The goal is to see if the drug improves the progression of the disease in patients with systemic sclerosis and what the side effects are
•To assess the efficacy of treatment with TCZ 162 mg SC versus placebo SC given every week to patients with SSc, at Week 24 using the mRSS •To assess the safety of treatment with TCZ 162 mg SC versus...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's disease
Efficacy Objectives Induction Phase • To evaluate the efficacy of etrolizumab dose regimens compared with placebo in inducing CDAI remission, defined as a CDAI score < 150 at the end of the Inductio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Clinical Trial Evaluating the Addition of a Drug, Onartuzumab, to standard treatment (Erlotinib) in Patients with a Specific Generic Type of Lung Cancer
- To determine the efficacy of onartuzumab+erlotinib compared with placebo+erlotinib, as measured by progression-free survival (PFS) assessed by the investigator.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer
To assess the clinical safety and feasibility of T-DM1 after the completion of doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (5-FU)/epirubicin/ cyclophosphamide (FEC) adjuvant/neoadjuvant chemot...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
8
9
10
11
12
13
14
15
16
17
Next